Journal Article

DKFZ-2017-04890

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.

Kayser, S. (First author)DKFZ* ; Benner, A.DKFZ* ; Thiede, C. ; Martens, U. ; Huber, J. ; Stadtherr, P. ; Janssen, J. W. G. ; Röllig, C. ; Uppenkamp, M. J. ; Bochtler, T.DKFZ* ; Hegenbart, U. ; Ehninger, G. ; Ho, A. D. ; Dreger, P. ; Krämer, A. (Last author)DKFZ*

2016
Nature Publishing Group London [u.a.]

This record in other databases:  

Please use a persistent id in citations: doi:10.1038/bcj.2016.46

Abstract: The objective was to evaluate the prognostic impact of pre-transplant minimal residual disease (MRD) as determined by real-time quantitative polymerase chain reaction in 67 adult NPM1-mutated acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). Twenty-eight of the 67 patients had a FLT3-ITD (42%). Median age at transplantation was 54.7 years, median follow-up for survival from time of allografting was 4.9 years. At transplantation, 31 patients were in first, 20 in second complete remission (CR) and 16 had refractory disease (RD). Pre-transplant NPM1 MRD levels were measured in 39 CR patients. Overall survival (OS) for patients transplanted in CR was significantly longer as compared to patients with RD (P=0.004), irrespective of whether the patients were transplanted in first or second CR (P=0.74). There was a highly significant difference in OS after allogeneic HSCT between pre-transplant MRD-positive and MRD-negative patients (estimated 5-year OS rates of 40 vs 89%; P=0.007). Multivariable analyses on time to relapse and OS revealed pre-transplant NPM1 MRD levels >1% as an independent prognostic factor for poor survival after allogeneic HSCT, whereas FLT3-ITD had no impact. Notably, outcome of patients with pre-transplant NPM1 MRD positivity >1% was as poor as that of patients transplanted with RD.

---

Contributing Institute(s):

1. KKE Molekulare Hämatologie/Onkologie (G330)
2. Biostatistik (C060)

Research Program(s):

1. 317 - Translational cancer research (POF3-317) (POF3-317)

Appears in the scientific report 2016

---

Database coverage:
; ; ; BIOSIS Previews ; Current Contents - Clinical Medicine ; DOAJ Seal ; IF < 5 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection

---